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Background: More than one-third of the patients with ischemic stroke caused by an 
intracranial large vessel occlusion do not recover to functional independence despite 
fast and successful recanalization by acute mechanical thrombectomy (MT). This may 
partially be explained by incomplete microvascular reperfusion. Some antithrombotics, 
e.g., antiplatelet agents and heparin, may be able to restore microvascular reperfusion. 
However, antithrombotics may also increase the risk of symptomatic intracranial hemor-
rhage (sICH). The aim of this review was to assess the potential safety and functional out-
come of periprocedural antiplatelet or heparin use during acute MT for ischemic stroke.
methods: We systematically searched PubMed, Embase, Medline, Web of Science, 
and Cochrane for studies investigating the safety and functional outcome of periproce-
dural antiplatelet or heparin treatment during acute MT for ischemic stroke. The primary 
outcome was the risk for sICH. Secondary outcomes were functional independence 
after 3–6 months (modified Rankin Scale 0–2) and mortality within 6 months.
Results: 837 studies were identified through the search, of which 19 studies were included. 
The sICH risks of the periprocedural use of antiplatelets ranged from 6 to 17%, and for heparin 
from 5 to 12%. Two of four studies reporting relative effects of the use of antithrombotics are 
pointing toward an increased risk of sICH. Among patients treated with antiplatelet agents, 
functional independence varied from 23 to 60% and mortality from 18 to 33%. For heparin, 
this was, respectively, 19–54% and 19–33%. The three studies presenting relative effects 
of antiplatelets on functional independence showed neutral effects. Both studies reporting 
relative effects of heparin on functional independence found it to increase this chance.
conclusion: Randomized controlled trials investigating the effect of periprocedural 
antithrombotic treatment in MT are lacking. Some observational studies report a slight 
increase in sICH risk, which may be acceptable because they also suggest a beneficial 
effect on functional outcome. Therefore, randomized controlled trials are warranted to 
address the question whether the potentially higher risk of sICH could be outweighed by 
improved functional outcome.
Keywords: ischemic stroke, periprocedural, heparin, antiplatelet agents, antithrombotic agents, mechanical 
thrombectomy, endovascular treatment
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BacKGROUND
The introduction of endovascular treatment by means of acute 
mechanical thrombectomy (MT) has been a major change in the 
emergent treatment of ischemic stroke caused by an intracranial 
large vessel occlusion. An individual patient data meta-analysis 
of randomized trials showed that this approach is highly effective 
(1). In that meta-analysis, MT significantly improved functional 
outcome at 90 days, with a number needed to treat of 2.6 to reduce 
disability by one level on the modified Rankin Scale (mRS). Still, 
approximately one-third of the patients do not recover to func-
tional independence despite fast and complete recanalization by 
MT (2, 3). This could partially be attributable to microvascular 
dysfunction also known as incomplete microvascular reperfu-
sion (IMR). The concept of IMR stems from observations in 
the non-human primate of focal “no-reflow” following focal 
ischemia—caused by adhesion of polymorphonuclear leukocytes 
(4–6), and/or platelet-fibrin occlusions (7) within the downstream 
microvasculature—that could be prevented by anti-leukocyte or 
antithrombotic strategies. More recently, this concept has been 
described again (8). Antiplatelet agents in experimental systems 
have shown to prevent the microvascular occlusive events in 
both non-human primate and mouse models and to improve 
outcome (9, 10). Also heparin may be of additional value to MT, 
by preventing microthrombus formation and microvascular 
obstruction and potentially restore microvascular reperfusion. 
It has been suggested that microvascular obstructions could 
arise from neutrophil extracellular trap (NET) formation (11). 
NET formation can be dissolved by heparin, but not by tissue 
plasminogen activator (tPA) (12, 13). As antiplatelet agents and 
heparin seem promising in their ability to restore microvascular 
function, these drugs might contribute to the recovery of patients 
with ischemic stroke undergoing acute MT. A direct test of this 
hypothesis in humans has not yet taken place. An important 
disadvantage of both antiplatelet and heparin use in the setting 
of focal cerebral ischemia is the increased risk of intracranial 
hemorrhage. Symptomatic intracranial hemorrhage (sICH) leads 
to severe handicap or death in almost all patients (14). A ran-
domized trial—in which patients with an ischemic stroke were 
either assigned to intravenous (IV) antiplatelet agents within 
90 min after starting treatment with IV recombinant tPA or to 
no antiplatelet agents—was stopped before the intended conclu-
sion due to non-superior outcomes and a higher risk of sICH 
in the group that received antiplatelet agents (15). Although the 
absolute sICH risk associated with acute antiplatelet administra-
tion was low (4.3%), concerns remain about this detrimental side 
effect. These concerns are also present with regard to the use of 
heparin in ischemic stroke. This may be due to the results of the 
International Stroke Trial, in which 19,435 patients were rand-
omized to receive antiplatelet agents, heparin, both or neither 
within 48 h after symptom onset (16). In this study, the beneficial 
results (i.e., reduced risk of recurrent stroke and improved 
functional outcome) were offset by a higher sICH risk. Again, 
the absolute sICH risk was low in this trial, even in the high-dose 
group receiving 12,500  IU twice daily (2.0%). Yet, the balance 
between risk and benefit of these antithrombotic drugs for 
patients with ischemic stroke is uncertain in the setting of acute 
MT. Therefore, the aim of this review was to assess the potential 
safety and functional outcome of periprocedural antiplatelet or 
heparin use during acute MT for ischemic stroke.
metHODS
Search Strategy
A search strategy was developed in collaboration with a bio-
medical information specialist to systematically search PubMed, 
Embase, Medline, Web of Science, and Cochrane. The search was 
conducted in November 2017 and updated in March 2018. Two 
independent reviewers (RG and VC) screened all identified 
articles on titles and abstracts for eligibility. Articles identified as 
potentially eligible underwent a full text review. Disagreements 
between reviewers were resolved by a consensus meeting with a 
third reviewer (BR). The complete search strategy is listed as sup-
plemental material (Data Sheet S1 in Supplementary Material).
inclusion and exclusion criteria
Studies were eligible for inclusion when:
– Periprocedural [consisting of prior, acute (<6  h) or early 
(6–24  h)], oral or parenteral, antiplatelet agents or heparin 
were used in patients who underwent MT for ischemic stroke.
– Posttreatment sICH was reported.
– English abstract was available.
– Patients were 18 years or older.
Studies were excluded when:
– Antithrombotic agents other than antiplatelet agents and hepa-
rin were used.
– The specific number of patients with prior antiplatelet agents 
could not be extracted, and differentiation between outcomes 
of patients with and without prior antiplatelet use was not 
possible.
– Less than 50% of the endovascular treated patients were treated 
with MT.
– Less than 20 patients underwent MT.
In addition, studies reporting on patients with “tandem 
lesions” (i.e., an intracranial large vessel occlusion with simul-
taneous ipsilateral extracranial carotid occlusion) treated with 
intracranial MT with or without emergency carotid artery stent-
ing were included through bibliographic review of the included 
studies. In these studies, antithrombotics were used as a part of 
protocol-based care to prevent stent occlusion. Finally, large ran-
domized controlled trials (RCTs) investigating the effectiveness 
of MT, and in which periprocedural antithrombotics were used, 
were included through bibliographic reviewing.
Data extraction and Synthesis
We developed a data extraction form based on elements of the 
Cochrane Consumers and Communication Review Group’s 
data extraction template (17). Two reviewers extracted the data 
independently: one reviewer extracted all the data (RG) and the 
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other reviewer extracted 25% of the data (VC). Extracted data 
were checked during consensus meetings with three reviewers 
(RG, VC, and BR). For each included study, we aimed to specifi-
cally extract the available data for the patients treated with MT 
or the most representative group. The following information was 
extracted: study design, study population characteristics [sample 
size, age, National Institutes of Health Stroke Scale (NIHSS) 
at baseline, and occlusion location], recanalization therapy 
[administration of IV plasminogen activators, administration 
of intraarterial (IA) plasminogen activators, treatment with 
MT, and time from symptom onset to recanalization therapy]; 
study treatment and contrast [type of antithrombotic treat-
ment, indication for antithrombotic administration, time from 
symptom onset to antithrombotic treatment, number of patients 
treated with antithrombotic treatment, and information about 
the control group (when available)]; safety (sICH and all-cause 
mortality within 6 months); and functional outcome (functional 
independence after 3–6  months, expressed as a mRS score of 
0–2) (18, 19). Special note was made of the definition of sICH 
in each study.
When available, study characteristics were reported by mean 
(SDs) or median (interquartile ranges). Outcomes were reported 
as numbers of cases and percentages. When a comparison was 
performed or a contingency table could be prepared, odds ratios 
for both safety (sICH and all-cause mortality) and functional 
(mRS 0–2) outcomes were reported, with 95% confidence 
intervals (CIs). If present, adjusted odds ratios (aORs) were also 
reported. When data were unclear or missing, we extracted data 
from the related original study (when available) or approached 
the corresponding author for clarification. Data were reported 
according to the Preferred Reporting Items for Systematic reviews 
and Meta-analyses (PRISMA) Statement (20). The checklist 
can be found in the supplementary material (Data Sheet S2 in 
Supplementary Material).
ReSULtS
Study Selection
The systematic literature search yielded a total of 1,270 studies 
(Figure  1). After removing duplicates, 837 articles remained, 
of which all titles and abstracts were screened. Full text of 17 
articles was retrieved and assessed for eligibility. In addition, 
eight eligible studies were identified through bibliographic review 
of the included studies. Seven studies were identified in which 
tandem lesions were investigated, and one RCT investigating 
the effectiveness of MT was identified, in which periprocedural 
antithrombotics were used. A total of 19 articles met the selection 
criteria and were included in the review (21–39).
thrombectomy and Antiplatelet Use
We identified six studies investigating the periprocedural use of 
antiplatelet agents (22, 24, 31, 32, 36, 39). These studies include 
five cohort studies with sample sizes between 35 and 231 patients 
(22, 24, 31, 36, 39), and one post hoc analysis on a phase III RCT of 
233 patients (Table 1) (32). The occlusion location varied between 
anterior circulation only (one study) (32), posterior circulation 
only (one study) (24), and both anterior and posterior circulation 
(three studies) (22, 36, 39). The occlusion location could not be 
retrieved in one study (31). In the cohort studies, 57–100% of 
the study population underwent MT, and in the post hoc analysis 
on phase III RCT data, all patients (in whom the effect of anti-
platelet agents was investigated) underwent MT. The indication 
for antiplatelet use was mainly based on comorbidity (prior use) 
and prevention of re-occlusion of the vessel after recanalization. 
The sICH risk for periprocedural antiplatelet use ranged from 6 
to 17%. Among the patients using antiplatelet agents, mortality 
varied from 18 to 33%, and functional independence from 23% 
to 60% (Table 2).
Four studies reported unadjusted relative effects of antiplatelet 
agents on the risk of sICH (22, 32, 36, 39). Antiplatelet use was 
associated with a higher relative effect on sICH in two studies 
in which patients were on prior antiplatelet treatment (OR, 4.80; 
95% CI, 1.77–13.02, and OR, 5.43; 95% CI, 1.46–20.13) (32, 36), 
and a neutral effect in the other studies in which patients received 
acute antiplatelet treatment in one and were on prior antiplatelet 
treatment in the other (OR, 0.92; 95% CI, 0.24–3.46, and OR, 
0.81; 95% CI, 0.25–2.68) (22, 39). Only one study adjusted the 
estimate of the relative sICH risk, attributable to antiplatelet use, 
for prognostic factors (glucose level and baseline NIHSS), but not 
for prior comorbidity or reperfusion (36). The population of this 
study was heterogeneous, concerning patients who received IA 
plasminogen activator and/or MT. The absolute sICH risk was 
13% among patients receiving prior antiplatelet treatment and 3% 
among patients who did not. Prior use of an antiplatelet agent 
was an independent risk factor for sICH (aOR, 8.03; 95% CI, 
1.83–41.70).
Three studies reported unadjusted effect estimates of anti-
platelet use on mortality and functional independence (22, 32, 
39). The relative effect on mortality was neutral in two studies 
(OR, 0.75; 95% CI, 0.34–1.67, and OR, 0.97; 95% CI, 0.50–1.85) 
(22, 39) and higher in the other (OR, 2.46; 95% CI, 1.27–4.76) 
(32), when antiplatelet agents were used. In all studies, the effect 
on functional independency was neutral (OR, 0.61; 95% CI, 
0.32–1.17, and OR, 0.54; 95% CI, 0.28–1.05, and OR, 1.11; 95% 
CI, 0.63–1.97).
The post hoc analysis of the Multicenter Randomized CLinical 
trial of Endovascular treatment for Acute ischemic stroke in the 
Netherlands (MR CLEAN) was the only study in which prior 
antiplatelet use was directly compared to no prior antiplatelet 
use in patients who underwent acute MT (32). Prior antiplatelet 
use was associated with a higher risk of sICH (OR, 4.80; 95% 
CI, 1.77–13.02) and mortality (OR, 2.46; 95% CI, 1.27–4.76). 
However, prior antiplatelet use did not interact with MT treatment 
effect and safety parameters like sICH. Moreover, among pati-
ents with successful recanalization, patients on prior antiplatelet 
use were twice as likely to have a favorable functional outcome 
(39 vs. 18%, Pinteraction = 0.025). One other study that investigated 
the recanalization rate found that patients on prior antiplatelet 
treatment have higher odds for successful recanalization (39).
antiplatelet Use in Patients with tandem 
Lesions
We identified eight cohort studies in which patients with tan-
dem lesions—that required intracranial MT with or without 
FiGURe 1 | Flowchart of the systematic literature search.
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combined emergency carotid artery stenting—received anti-
platelet agents as mandatory protocol-based care to prevent stent 
occlusion (Table 3) (21, 23, 25, 28–30, 34, 35). Antithrombotic 
agents in these studies included eptifibatide, tirofiban, abcixi-
mab, acetylsalicylic acid, clopidogrel, and heparin, alone or in 
combination. The observed sICH risk in the included studies 
ranged from 0 to 17% (Table  4). Mortality ranged from 0 to 
39% and functional independence from 29 to 70%. No relative 
effects on sICH, mortality, or functional independence were 
reported.
thrombectomy and Heparin Use
Four studies investigated the periprocedural use of heparin 
(Table 5) (27, 33, 37, 38). Two studies were post hoc analyses of 
RCT data (33, 37), one was a cohort study (38), and one was an 
RCT investigating the efficacy of acute endovascular treatment, 
which could include periprocedural heparin use (27). All stud-
ies investigated the use of unfractionated heparin (UFH). Both 
anterior and posterior circulation occlusions were included in all 
studies. The administered heparin dose was reported in all studies 
and varied between 2,000 and 5,000 IU. Heparin administration 
taBLe 1 | Characteristics of included studies investigating periprocedural antiplatelet use in patients with ischemic stroke who underwent acute MT.
Study characteristics Population characteristics Recanalization therapy Study treatment and contrast
Reference Study 
design
N age NiHSS 
score at 
baseline
Occlusion 
location
iv tPa,  
n/N (%)
ia tPa, 
n/N (%)
mt,  
n/N (%)
time from 
symptom 
onset to 
recanalization 
therapy (min)
antithrombotic 
treatment
indication for 
antithrombotic 
treatment
time from 
symptom 
onset to 
antithrombotic 
treatmenta
treatment,  
n/N (%)
control control,  
n/N (%)
Broeg-
Morvay 
et al.a (22)
Prospective 
cohort
231b Meanc:  
69 (± 14)
Medianc: 
15 (2–37)
Anterior + posterior 
circulation
231/231 
(100%)
69/231 (30%) 212/231 
(92%)
Meanc: 270 (±83) ASA loading 
dose (median: 
300 mg)
Prevention of 
re-occlusion
Acute 50/231 (22%) No ASA 181/231 (78%)
Stenting
Ernst  
et al. (24)
Retrospective 
cohort
54b Mean: 65 Median: 
32
Posterior circulation 0/54 (0%) 54/54 (100%) 31/54 (57%) Median: 198 IV abciximab 
bolus (0.25 mg/
kg) followed 
by continuous 
infusion, or, 
tirofiban bolus 
(10 μg/kg) 
followed by 
continuous 
infusion
Protocol-based 
care
Acute 54/54 (100%) NR NR
Memon 
et al. (31)
Prospective 
cohort
35b Mean: 62 Median:  
13 (5–22)
NR 2/35 (6%) 12/35 (34%) ≥20/35 
(≥57%)
Median: 230 IA eptifibatide 
bolus (180 μg/kg) 
Presence of 
distal emboli
Acute 35/35 (100%) NR NR
Inaccessible 
location by MT
Prevention of 
re-occlusion
Mulder 
et al. (32)
Post hoc 
analysis on 
phase III RCT
233 Median: 
66 (55–76)
Median: 
17 (14–21)
Anterior circulation 203/233 
(87%)
24/233 (10%) 233/233 
(100%)
Median: 260 
(210–313)
Any antiplatelet 
use (single and 
dual)
Comorbidity Prior use 64/233 (27%) No 
antiplatelet 
use
169/233 (73%)
Pandhi 
et al. (39)
Retrospective 
cohort
217 Meanc: 60 
(±14)
Medianc: 
16 (12–21)
Anterior + posterior 
circulation
141/217 
(65%)
0/217 (0%) 217/217 
(100%)
Mean: 361 Any antiplatelet 
use (single and 
dual)
Comorbidity Prior use 71/217 No 
antiplatelet 
use
146/217 (67%)
Sugiura 
et al. (36)
Prospective 
cohort
204b Mean: 71 
(± 13)
Median: 
18 (13–22)
Anterior + posterior 
circulation
80/204 
(39%)
42/204 (21%) 170/204 
(83%)
Mean: 188 
(±101)
Any antiplatelet 
use (single and 
dual)
Comorbidity Prior use 48/204 (24%) No 
antiplatelet 
use
156/204 (76%)
Characteristics of the included studies are presented by sample size (percentage), means (SDs), medians (interquartile ranges), or by remarks.
ASA, acetylsalicylic acid; IA, intraarterial; IV, intravenous; MT, mechanical thrombectomy (by means of stent retriever or aspiration); NIHSS, National Institutes of Health Stroke Scale; NR, not reported; RCT, randomized controlled trial; 
tPA, tissue plasminogen activator.
aTime from symptom onset to antithrombotic treatment was divided into acute treatment administration (<6 h) and early administration (6–24 h).
bNot solely MT.
cExtracted data from the subgroup that received antiplatelet agents.
5
van de G
raaf et al.
P
eriprocedural A
ntithrom
botics D
uring M
T
Frontiers in N
eurology | w
w
w
.frontiersin.org
A
pril 2018 | Volum
e 9 | A
rticle 238
ta
B
Le
 2
 | 
O
ut
co
m
es
 o
f i
nc
lu
de
d 
st
ud
ie
s 
in
ve
st
ig
at
in
g 
pe
rip
ro
ce
du
ra
l a
nt
ip
la
te
le
t u
se
 in
 p
at
ie
nt
s 
w
ith
 is
ch
em
ic
 s
tr
ok
e 
w
ho
 u
nd
er
w
en
t a
cu
te
 m
ec
ha
ni
ca
l t
hr
om
be
ct
om
y.
R
ef
er
en
ce
si
c
H
, n
/N
 (%
)
m
o
rt
al
it
y,
 n
/N
 (%
)
m
R
S
 (0
–2
), 
n
/N
 (%
)
si
c
H
, O
R
 (9
5%
 c
i)
m
o
rt
al
it
y,
 O
R
 
(9
5%
 c
i)
m
R
S
 (0
–2
), 
O
R
 
(9
5%
 c
i)
si
c
H
, a
O
R
 
(9
5%
 c
i)
m
o
rt
al
it
y,
 
aO
R
  
(9
5%
 c
i)
m
R
S
 
(0
–2
), 
aO
R
 
(9
5%
 c
i)
B
ro
eg
-M
or
va
y 
et
 a
l. 
(2
2)
T 
= 
3/
50
 (6
%
), 
C
 =
 1
0/
18
1 
(6
%
)b
T 
= 
9/
50
 (1
8%
), 
C
 =
 4
1/
18
1 
(2
3%
)
T 
= 
17
/5
0 
(3
4%
), 
C
 =
 8
3/
18
1 
(4
6%
)
0.
92
 (0
.2
4–
3.
46
)
0.
75
 (0
.3
4–
1.
67
)
0.
61
 (0
.3
2–
1.
17
)
N
R
N
R
N
R
E
rn
st
 e
t a
l. 
(2
4)
T 
= 
7/
54
 (1
3%
)c
T 
= 
18
/5
4 
(3
3%
)
T 
= 
15
/5
4 
(2
8%
)
N
R
N
R
N
R
N
R
N
R
N
R
M
em
on
 e
t a
l. 
(3
1)
T 
= 
5/
35
 (1
4%
)d
T 
= 
8/
35
 (2
3%
)
T 
= 
21
/3
5 
(6
0%
)
N
R
N
R
N
R
N
R
N
R
N
R
M
ul
de
r 
et
 a
l. 
(3
2)
T 
= 
11
/6
4 
(1
7%
), 
C
 =
 7
/1
69
 (4
%
)d
T 
= 
21
/6
4 
(3
3%
), 
C
 =
 2
8/
16
9 
(1
7%
)
T 
= 
15
/6
4 
(2
3%
), 
C
 =
 6
1/
16
9 
(3
6%
)
4.
80
 (1
.7
7–
13
.0
2)
2.
46
 (1
.2
7–
4.
76
)
0.
54
 (0
.2
8–
1.
05
)
N
R
N
R
N
R
P
an
dh
i e
t a
l. 
(3
9)
T 
= 
4/
71
 (6
%
), 
C
 =
 1
0/
14
6 
(7
%
)e
T 
= 
18
/7
1 
(2
5%
), 
C
 =
 3
8/
14
6 
(2
6%
)
T 
= 
33
/7
1 
(5
0%
), 
C
 =
 6
4/
14
6 
(4
8%
)
0.
81
 (0
.2
5–
2.
68
)
0.
97
 (0
.5
0–
1.
85
)
1.
11
 (0
.6
3–
1.
97
)
N
R
N
R
N
R
S
ug
iu
ra
 e
t a
l. 
(3
6)
T 
= 
6/
48
 (1
3%
), 
C
 =
 4
/1
56
 (3
%
)f
N
R
N
R
5.
43
 (1
.4
6–
20
.1
3)
N
R
N
R
8.
03
 
(1
.8
3–
41
.7
0)
a
N
R
N
R
aO
R
, (
ad
ju
st
ed
) o
dd
s 
ra
tio
; C
, c
on
tr
ol
; C
I, 
co
nfi
de
nc
e 
in
te
rv
al
; m
R
S
, m
od
ifi
ed
 R
an
ki
n 
S
ca
le
; N
R
, n
ot
 r
ep
or
te
d;
 s
IC
H
, s
ym
pt
om
at
ic
 in
tr
ac
ra
ni
al
 h
em
or
rh
ag
e;
 T
, t
re
at
ed
 w
ith
 a
nt
ip
la
te
le
t a
ge
nt
; N
IH
S
S
, N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
  
S
tr
ok
e 
S
ca
le
.
a A
dj
us
te
d 
fo
r 
gl
uc
os
e 
le
ve
l a
nd
 N
IH
S
S
 a
t b
as
el
in
e.
b P
R
O
A
C
T-
II 
de
fin
iti
on
 (4
0)
.
c In
tr
ac
ra
ni
al
 h
em
or
rh
ag
e 
re
su
lti
ng
 in
 N
IH
S
S
 in
cr
ea
se
 o
f >
4 
or
 n
on
-d
efi
na
bl
e 
ne
ur
ol
og
ic
 s
ta
tu
s 
w
ith
 P
H
 a
nd
 s
ev
er
e 
m
as
s 
ef
fe
ct
 o
r 
su
ba
ra
ch
no
id
 h
em
or
rh
ag
e 
w
ith
 h
yd
ro
ce
ph
al
us
.
d In
tr
ac
ra
ni
al
 h
em
or
rh
ag
e 
re
su
lti
ng
 in
 N
IH
S
S
 in
cr
ea
se
 o
f ≥
4.
e S
IT
S
-M
O
S
T 
de
fin
iti
on
 (4
1)
.
f E
C
A
S
S
-I
I d
efi
ni
tio
n 
(4
2)
.
6
van de Graaf et al. Periprocedural Antithrombotics During MT
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 238
was a part of standard care in one study (38) and left to the 
discretion of the interventionalist in three studies (27, 33, 37). 
The observed risk of sICH varied between 5 and 12%, mortality 
between 19 and 33%, and functional independence between 19 
and 54% (Table 6).
Two studies reported an unadjusted effect estimate of heparin 
on the risk of sICH (33, 37). Both studies suggest that the effect 
of heparin use on sICH was neutral (8 vs. 11%; OR, 0.73; 95% 
CI, 0.11–4.77, and 12 vs. 4%; OR, 3.02; 95% CI, 0.91–9.97) 
(33, 37). Both studies also reported unadjusted effect estimates 
for mortality and functional independence. For the latter, also 
adjusted effects were provided. Both studies suggested that the 
effect on mortality is neutral (OR, 0.73; 95% CI, 0.23–2.28, and 
OR, 1.08; 95% CI, 0.54–2.16). After adjustment for prognostic 
factors [age and final revascularization success in one study (33), 
and intubation during procedure, postdevice TICI 2b–3, diabetes 
mellitus, baseline NIHSS score, study device (Trevo vs. Merci), 
time from symptom onset to arterial puncture (hours), and con-
gestive heart failure in the other (37)], periprocedural heparin use 
was positively associated with functional independence in both 
studies (aOR, 5.89; 95% CI, 1.34–25.92, and aOR, 5.30; 95% CI, 
1.70–16.48).
One study—which identified predictors for sICH—used a 
periprocedural loading dose of 3,000 to 5,000 IU UFH, followed 
by a continuous infusion of 1,000  IU per hour according to 
standard care (referred to as systemic heparinization) (38). The 
absolute risk of sICH was 5% in patients who underwent MT and 
received systemic heparinization. No relative effect of heparin 
on sICH was reported in this study, neither were mortality nor 
functional independence.
In the one RCT investigating the effectiveness of MT, peri-
procedural heparin use was left to the discretion of the treating 
interventionalist (27). When used, an IV dose of 2,000 IU UFH 
followed by a subsequent continuous infusion of 500 IU per hour 
until the end of the procedure was recommended for patients 
undergoing MT. The risk of sICH in the MT group was 5%. No 
relative effect on sICH was reported. Both mortality and func-
tional independence occurred in 19% of the patients in this study, 
but relative effects were not provided.
thrombectomy and antithrombotic 
combination Use
One study investigated different antithrombotic combination 
treatments in the early phase (<24  h) after ischemic stroke 
(26). Patients had relatively mild anterior or posterior circula-
tion occlusions with a median baseline NIHSS of 11. The early 
antithrombotic treatment consisted of antiplatelet, anticoagu-
lant, and combined antiplatelet with anticoagulant treatments 
(Table 7). The sICH rate in this study was 3%, mortality 8%, and 
functional independence 56% (Table  8). In this heterogeneous 
treatment group, in which patients received IV plasminogen acti-
vator, IA plasminogen activator, and/or MT, early antithrombotic 
treatment was not associated with sICH compared to standard 
antithrombotic treatment after multivariable adjustment (OR 
0.56, 95% CI: 0.35 to 2.10) (26). However, both the small group 
that actually received the combination therapy and the lack of 
taBLe 3 | Characteristics of included studies investigating patients with ischemic stroke caused by a “tandem lesions” who underwent acute MT with or without emergency extracranial carotid stenting, who received 
periprocedural antithrombotic drugs as protocol-based care.
Study characteristics Population characteristics treatment characteristics Study treatment
Reference Study 
design
N age NiHSS 
at 
baseline
Occlusion 
location
iv tPa,  
n/N (%)
ia tPa,  
n/N (%)
mt,  
n/N (%)
Stenting, 
 n/N (%)
time from 
symptom 
onset to 
recanalization 
therapy (min)
antithrombotic treatment when stent 
deployment was performed
time from 
symptom 
onset to 
antithrombotic 
treatmenta
Behme 
et al. (21)
Retrospective 
cohort
170 Median: 
64
Median: 
15
Anterior 
circulation
122/170 (72%) 0/170 (0%) 170/170 
(100%)
170/170 (100%) Median: 98 Periprocedural: Center A, loading dose 
of eptifibatide 180 μg/kg; Center B, loading 
dose of ASA 500 mg and clopidogrel 375 mg; 
Center C, loading dose of tirofiban (weight-
adapted); Center D, loading dose of ASA 
500 mg IV, plus 5,000 IU UFH or tirofiban
Acute
Postprocedural: Center A, continuous 
infusion eptifibatide for the first 24 h, hereafter 
dual antiplatelet treatment (loading clopidogrel 
300 mg and ASA 500 mg); Center B, 
continuation clopidogrel 75 mg/d and ASA 
100mg/d for 3 months; Center C, continuous 
infusion of tirofiban for the first 24 h, hereafter 
loading 500 mg ASA and 300 mg clopidogrel, 
continuation with 75 mg/d clopidogrel and 100 
m/d for 3 months; Center D, loading dose of 
clopidogrel 500 mg, hereafter ASA 100 mg/d 
and clopidogrel 75 mg/d for 3 months
Cohen 
et al. (23)
Retrospective 
cohort
24 Mean: 
66
Median: 
18 
(14–28)
Anterior 
circulation
10/24 (42%) 0/24 (0%) 24/24 
(100%)
24/24 (100%) Mean: 198 Periprocedural: Loading dose of 2,500 IU 
UFH (after femoral access, and confirmation 
for the need of stent implantation), patients 
not on antiplatelet therapy received a loading 
dose of 300 mg ASA
Acute
Postprocedural: Loading dose of clopidogrel 
300 mg added to ASA use. Two months 
dual therapy (clopidogrel 75 mg/d plus ASA 
100 mg/d)
Heck and 
Brown (25)
Retrospective 
cohort
23 Mean: 
70 
Median: 
17 (9–25)
Anterior 
circulation
7/23: (30%) 0/23 (0%) 23/23 
(100%)
23/23 (100%) NR Periprocedural: Loading dose of ASA 
300 mg in all patients, 12 patients loading 
dose of abciximab 0.25 mg/kg
NR
Postprocedural: Loading dose of clopidogrel 
600 mg if no abciximab was administered
Lockau 
et al. (28)
Retrospective 
cohort
37 Mean: 
63
Median: 
17 (3–30)
Anterior 
circulation
20/37: (54%) 0/37 (0%) 37/37 
(100%)
37/37 (100%) NR Periprocedural: Loading dose of tirofiban 
(weight adapted)
Acute
Postprocedural: Continuous infusion of 
tirofiban for the first 24 h, after exclusion of 
hemorrhage loading dose of ASA 500 mg and 
clopidogrel 300 mg. Hereafter, ASA 100 mg/d 
and clopidogrel 75 mg/d for 3 months
(Continued)
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Study characteristics Population characteristics treatment characteristics Study treatment
Reference Study 
design
N age NiHSS 
at 
baseline
Occlusion 
location
iv tPa,  
n/N (%)
ia tPa,  
n/N (%)
mt,  
n/N (%)
Stenting, 
 n/N (%)
time from 
symptom 
onset to 
recanalization 
therapy (min)
antithrombotic treatment when stent 
deployment was performed
time from 
symptom 
onset to 
antithrombotic 
treatmenta
Maurer 
et al. (30)
Retrospective 
cohort
43b Mean: 
68 
(±13)
Mean: 13 
(±5)
Anterior 
circulation
33/43 (77%) 20/43 (47%) 27/43 
(63%)
39/43 (91%) NR Periprocedural: Loading dose of ASA 
(500 mg) and IV UFH bolus (5,000 IU) before 
stent placement
NR
Postprocedural: Loading dose of clopidogrel 
600 mg or ticagrelor 180 mg
Marnat 
et al. (29)
Retrospective 
cohort
20 Mean: 
53
Mean: 18 Anterior 
circulation
15/20 (75%) 0/20 (0%) 20/20 
(100%)
5/20 (25%) Mean: 263 Periprocedural: Loading dose of ASA 
500 mg
Acute + early
Postprocedural: Local protocol
Rangel-
Castilla 
et al. (34)
Retrospective 
cohort
45 Mean: 
64
Mean: 14 Anterior 
circulation
15/45 (33%) 0/45 (0%) 45/45 
(100%)
45/45 (100%) Mean: 139 Periprocedural: Loading dose of ASA 
650 mg and clopidogrel 600 mg or ticagrelor 
180 mg. After confirmation of cervical 
occlusion heparinization at an activated 
coagulation time of ≥250 s
Acute
Postprocedural: Local protocol at 24 h
Stampfl 
et al. (35)
Retrospective 
cohort
24 Mean: 
67 
(±10)
Median: 
18 
(15–22)
Anterior 
circulation
22/24 (92%) 0/24 (0%) 24/24 
(100%)
24/24 (100%) Mean: 230 
(±131)
Periprocedural: 17 patients continuous 
infusion of tirofiban; 5 patients loading dose of 
ASA and clopidogrel and UFH; 2 patients (on 
prior antiplatelet) loading dose of UFH
Acute + early
Postprocedural: Patients on tirofiban 
continuation for the first 24–48 h; all patients 
100 mg/d ASA and clopidogrel 75 mg/d
Characteristics of the included studies are presented by sample size (percentage), mean (SD), median (interquartile ranges), or by remarks.
ASA, acetylsalicylic acid; IA, intraarterial; IV, intravenous; MT, mechanical thrombectomy (by means of stent retriever or aspiration); NR, not reported; tPA, tissue plasminogen activator; UFH, unfractionated heparin.
aTime from symptom onset to antithrombotic treatment was divided into acute administration (<6 h) and early administration (6–24 h).
bNot solely MT.
taBLe 3 | Continued
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taBLe 4 | Outcomes of included studies investigating patients with ischemic 
stroke caused by a “tandem lesions” who underwent acute mechanical 
thrombectomy with or without emergency extracranial carotid stenting, who 
received periprocedural antithrombotic drugs as protocol-based care.
Reference sicH,  
n/N (%)
mortality,  
n/N (%)
mRS (0–2),  
n/N (%)
Behme et al. (21) 15/170 (9%)a 32/170 (19%) 62/170 (36%)
Cohen et al. (23) 0/24 (0%)b 2/24 (8%) 13/24 (54%)
Heck and Brown (25) 5/23 (2%)c 9/23 (39%) 12/23 (52%)
Lockau et al. (28) 4/37 (11%)d 7/37 (19%) 17/37 (46%)
Marnat et al. (29) 1/20 (5%)a 0/20 (0%) 14/20 (70%)
Maurer et al. (30) 5/43 (12%)e 9/43 (21%) 14/43 (33%)
Rangel-Castilla et al. (34) 2/45 (4%)f 5/45 (11%) 22/45 (49%)
Stampfl et al. (35) 4/24 (17%)a 4/24 (17%) 7/24 (29%)
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, 
symptomatic intracranial hemorrhage.
aECASS-II definition (42).
bIntracranial hemorrhage resulting in NIHSS increase of ≥4 within 36 h.
cSITS-MOST definition (41).
dIntracranial hemorrhage resulting in NIHSS increase of >4.
eNo specific definition of sICH given.
fIntracranial hemorrhage resulting in NIHSS increase of ≥4 or death.
9
van de Graaf et al. Periprocedural Antithrombotics During MT
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 238
subanalyses limit the ability to draw conclusions on combination 
antithrombotic treatments used during MT. This study is men-
tioned separately, because it did not report outcomes by separate 
antithombotic regimens.
DiScUSSiON
Based on the available literature, an increased sICH risk for both 
periprocedural administration of antiplatelet agents and heparin 
may be expected. Notwithstanding this higher risk of sICH, 
we found promising results of early antithrombotics regarding 
functional outcome in ischemic stroke patients undergoing MT. 
Future studies, especially RCTs, need to determine if the poten-
tially higher sICH risk can be outweighed by improved functional 
outcome.
antiplatelet agents
Most studies reported a small but noteworthy higher risk of sICH. 
Only one study performed multivariable adjustment, in which 
an aOR of 8.03 was found (36). However, the CI was wide (95% 
CI, 1.83–41.70), and there may have been residual confounding. 
Promising results on functional outcome were seen when patients 
were on prior antiplatelet treatment and a complete recanaliza-
tion was established, as patients were twice as likely to have a 
favorable functional outcome (32). This analysis has not been 
done by the other included studies. Furthermore, the effect of 
adding antiplatelet agents may have a different result in patients 
who were treated with IV rtPA (15). However, none of the 
included studies performed this additional analysis. No further 
inference was possible.
Previous large randomized trials have investigated the isolated 
use of antiplatelet agents in general populations of patients with 
ischemic stroke (i.e., no endovascular treatment) (16, 43). In 
these studies, the absolute sICH risk associated with antiplatelet 
administration was approximately 1% when the treatment was 
initiated within 48 h from symptom onset. MT with or without 
prior IV tPA bears a sICH risk of 4.4%, ranging from 0 to 7.7% 
in the large trials (1). The MR CLEAN post hoc analysis had not 
found an interaction between antiplatelet agents and the effect of 
MT on functional outcome. Taken together, the risk of sICH in 
patients who undergo MT for ischemic stroke within 6 h and the 
risk of sICH contributable to antiplatelet agents, this expected 
risk of sICH is in line with the range from 6 to 17% presented in 
our review (1, 16).
On the whole, periprocedural use of antiplatelet agents may be 
a useful adjunct, albeit with a higher sICH risk.
Heparin
Although at least one of the reported studies suggested that 
periprocedural heparin increased the risk of sICH (37), both 
studies that reported a relative effect of heparin on functional 
independence showed favorable results (33, 37). However, the 
true impact of adjunct heparin use remains difficult to deter-
mine in these observational studies. Substantial between-center 
variability in the use of periprocedural heparin exists. Indications 
varied from no heparin use, to use at the discretion of the inter-
ventionalist, and to standard care.
A large RCT has previously investigated the isolated effect 
of heparin treatment within 48  h in a general population of 
patients with ischemic stroke (i.e., no endovascular treatment), 
which resulted in an absolute sICH risk of 1.2% (16). Taken 
together with the sICH risk of MT, this is in line with the sICH 
range of 5–12% presented in our review (1, 16). This frequency 
of sICH is also comparable to the sICH risk in patients treated 
with acute systemic recombinant tPA in the NINDS and ECASS-
III trials (44, 45). In the PROlyse (recombinant prourokinase) 
in Acute Cerebral Thromboembolism (PROACT) trial—the 
only randomized double-blind placebo-controlled trial of IA 
treatment—the use of heparin, at the outset (acute phase) of 
IA delivery of placebo or recombinant prourokinase (pro-UK), 
was a significant predictor of both recanalization efficacy and 
sICH frequency (46). That study set the heparin protocol for 
the PROACT-II study, in which heparin was administered in 
combination with recombinant pro-UK. In PROACT-II, both 
patients in the IA treatment arm and the control arm received 
heparin; 4,000 IU in total. A non-significant increase of 8% in 
sICH risk in the endovascular treatment arm compared to the 
control arm of the study was observed in the univariable analysis, 
but also an improvement in functional outcome just significant 
after stratification for stroke severity (40). Based on the available 
literature, the overall higher risk of sICH may be offset by the 
improved odds for a functional independence when heparin is 
used periprocedurally.
Strengths and Limitations
In light of two other reviews describing periprocedural 
antithrombotic use in ischemic stroke management, the strength 
of this study is the specific focus on MT, the emphasis on safety, 
the performance of a thorough systematic literature search and 
the identification of studies not included in both other reviews 
(47, 48). Another strength is the structured reporting of data 
according to the PRISMA Statement.
taBLe 5 | Characteristics of included studies investigating periprocedural heparin use in patients with ischemic stroke who underwent acute MT.
Study characteristics Population characteristics Recanalization therapy Study treatment and contrast
Reference Study 
design
N age NiHSS 
score at 
baseline
Occlusion 
location
iv tPa,  
n/N (%)
ia tPa,  
n/N (%)
mt,  
n/N (%)
time from 
symptom 
onset to 
recanalization 
therapy (min)
antithrombotic 
treatment
indication for 
antithrombotic 
treatment
time from 
symptom 
onset to 
antithrombotic 
treatmenta
treatment,  
n/N (%)
control control,  
n/N (%)
cohort studies and post hoc analyses
Enomoto 
et al. (38)
Prospective 
cohort
704b NR NR Anterior + posterior 
circulation
440/704 
(63%)
123/704 
(17%)
409/704 
(58%)
NR Standard UFH 
bolus of 3,000–
5,000 IU, followed 
by 1,000 IU/h 
to maintain ACT 
(250–350 s)
Standard care Acute + early 409/704c (58%) NR NR
Nahab et al. 
(33)
Post hoc 
analysis on 
phase IIB 
RCT
51 Meand: 75 
(±10)
Meand: 21 
(±9)
Anterior + posterior 
circulation
18/51 (35%) 13/51 (25%) 51/51 
(100%)
Meand:  
269 (±86)
UFH (median: 
3,000 IU) 
Discretion 
interventionalist
Acute + early 24/51 (41%) No 
heparin
27/51 (53%)
Winningham 
et al. (37)
Post hoc 
analysis on 
phase III 
RCT
173 Mean: 68 
(±14)
Median: 
19 (15–21)
Anterior + posterior 
circulation
NR 96/173 
(55%)
173/173 
(100%)
<480 UFH (mean: 
4,016 IU)
Discretion 
interventionalist
Acute + early 58/173 (34%) No 
heparin
115/173 (66%)
Rcts investigating effectiveness of endovascular strategies
Kidwell  
et al. (27)
Phase IIB 
RCT
64 Meane: 66 
(±13)
Mediane: 
16 (12–18)
Anterior circulation 44/64 (44%) NR 64/64 
(100%)
Meane:  
318 (±96)
Recommended 
UFH bolus of 
2,000 IU, followed 
by 500 IU/h until 
end of procedure
Discretion 
interventionalist
Acute + early NR NR NR
Characteristics of the included studies are presented by sample size (percentage), mean (SDs), median (interquartile ranges), or by remarks.
IA, intraarterial; IU, international unit; IV, intravenous; MT, mechanical thrombectomy (by means of stent retrievers or aspiration); NIHSS, National Institutes of Health Stroke Scale; NR, not reported; RCT, randomized controlled trial; tPA, 
tissue plasminogen activator; UFH, unfractionated heparin.
aTime from symptom onset to antithrombotic treatment was divided in acute administration (<6 h) and early administration (6–24 h).
bNot solely MT.
cAntithrombotic treatment was used in all patients in the MT group.
dExtracted data from the subgroup that received heparin.
eExtracted data from the population that received penumbral embolectomy.
10
van de G
raaf et al.
P
eriprocedural A
ntithrom
botics D
uring M
T
Frontiers in N
eurology | w
w
w
.frontiersin.org
A
pril 2018 | Volum
e 9 | A
rticle 238
taBLe 6 | Outcomes of included studies investigating periprocedural heparin use in patients with ischemic stroke who underwent acute mechanical thrombectomy.
Reference sicH,  
n/N (%)
mortality,  
n/N (%)
mRS (0–2),  
n/N (%)
sicH, OR 
(95%ci)
mortality, 
OR (95%ci)
mRS (0–2), 
OR (95%ci)
sicH, 
aOR 
(95%ci)
mortality, 
aOR 
(95%ci)
mRS 
(0–2), aOR 
(95%ci)
cohort studies and post hoc analyses
Enomoto et al. (38) T = 20/409 (5%)c NR NR NR NR NR NR NR NR
Nahab et al. (33) T = 2/24 (8%)
C = 3/27 (11%)d
T = 8/24 (33%)
C = 11/27 (41%)
T = 13/24 (54%)
C = 8/27 (30%)
0.73  
(0.11 - 4.77)
0.73  
(0.23 - 2.28)
2.81  
(0.89 - 8.88)
NR NR 5.89 (1.34 
- 25.92)a
Winningham et al. (37) T = 7/58 (12%), 
C = 5/115 (4%)d
T = 17/58 (29%)
C = 32/115 (28%)
T = 23/58 (40%)
C = 30/115 (26%)
3.02  
(0.91 - 9.97)
1.08  
(0.54 - 2.16)
1.86  
(0.95 - 3.64)
NR NR 5.30 (1.70 
- 16.48)b
Rcts investigating effectiveness of endovascular strategies
Kidwell et al. (27) T = 3/64 (5%)e T = 12/64 (19%) T = 12/64 (19%) NR NR NR NR NR NR
C, control; CI, confidence interval; aOR, (adjusted) odds ratio; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NR, not reported; OR, odds ratio; 
sICH, symptomatic intracranial hemorrhage; T, treated with heparin.
aAdjusted for age and final revascularization success in one study.
bAdjusted for intubation during procedure, postdevice TICI 2b–3, diabetes mellitus, baseline NIHSS score, study device (Trevo vs. Merci), time from symptom onset to arterial 
puncture (hours), and congestive heart failure in the other.
aSITS-MOST definition (41).
bECASS-II definition (42).
cNo specific definition of sICH given.
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A limitation of this study is that some studies investigating 
periprocedural antithrombotic use in patients with tandem 
lesions were not identified by the initial search. This was because 
these studies did not provide keywords related to antithrombotic 
treatment use. When we became aware of this finding, we man-
aged this problem through an extensive bibliographic review of 
the included studies related to this topic. We discussed this issue 
with our biomedical information specialist, and due to heteroge-
neity among keywords used in these studies, an additional search 
was not feasible. It is possible that selection bias has occurred 
regarding this distinct pathology. On the whole, the risk of sICH 
seems acceptable in patients with tandem lesions, but the results 
of this subpopulation should be interpreted with caution, as the 
causal effects of previous ischemia, misery perfusion, and sud-
den reperfusion alongside that of antiplatelet treatment cannot 
be untwined. Because patients with tandem lesions constitute a 
distinct subpopulation with ischemic stroke, results may also be 
less generalizable to results in patients with intracranial occlu-
sions only, despite a similar treatment effect of acute MT in these 
patients (21). However, since limited evidence is available on 
the safety of periprocedural antiplatelet use in ischemic stroke 
patients undergoing acute MT, these studies provide valuable 
information and could therefore not be omitted.
Other limitations were the wide heterogeneity of inclusion 
criteria, treatment characteristics, and outcome definitions 
among studies. We found that some studies included patients 
with posterior circulation occlusion. These patients have a very 
poor prognosis with high mortality rates (49). Inclusion of these 
patients could have interfered with the reported outcomes. 
Furthermore, recanalization therapy varied among included 
studies from solely MT to more heterogeneous groups that 
received IV plasminogen activators, IA plasminogen activators, 
and/or MT. As no distinction was made in some studies, data 
specifically concerning patients who underwent MT could not 
always be extracted. This could have blurred the actual effect of 
periprocedural antithrombotic use in MT. Also, the use of IV 
plasminogen activator and IA plasminogen activator could have 
masked the actual sICH risk attributable to the antithrombotics. 
We also observed that the indication for antithrombotic admin-
istration depended on standard care, the discretion of the inter-
ventionist, and comorbidities, which dictated prior use. Patients 
with prior antiplatelet and heparin use were a priori more likely 
to have higher odds for worse outcome than the control group 
(due to comorbidity or occurrence of re-occlusion)—implying 
confounding by indication—which may hamper the interpreta-
tion of the outcomes and effect estimates. Even though few studies 
performed a multivariable analysis to adjust for confounding fac-
tors, this does not exclude the possibility that residual confound-
ing has influenced our findings. Interpretation of the results of 
our review has been hampered by missing data in most studies 
regarding example collateral status, infarct size, and underlying 
medical conditions for which antithrombotics were administered. 
Besides, we cannot rule out the possibility of publication bias. 
Moreover, we could not take dosing into account because of 
the limited number of studies reporting this. As we focused on 
periprocedural antiplatelet and heparin use, the effect of other 
antithrombotic drugs such as direct oral anticoagulants (DOACs) 
and coumarin derivatives remains unanswered. We chose not to 
include DOACs and coumarin derivatives as these drugs are not 
readily available to be administered in the acute phase. Besides, 
there is no evidence that DOACs and coumarin derivatives can 
restore microvascular obstruction. Furthermore, the time interval 
between symptom onset and start of antithrombotic treatment 
ranged from naught (prior use), through 0–6 h (studies admin-
istering the antithrombotic drugs in the acute phase during MT), 
to 6–24 h (studies postponing the antithrombotic treatment to the 
early postprocedural phase). Based on the experimental work, it 
seems likely that the acute use of specific antithrombotic agents 
could (I) decrease the incidence of sICH by avoiding the later 
stages of injury evolution and (II) potentially add to improvement 
of outcomes by preventing or limiting microvascular occlusion 
within the regions of ischemic injury (6, 7, 9). As the exact under-
lying pathway by which antithrombotics act—direct link between 
IMR and antithrombotics—was not in the scope of this review, 
this should be explored in future research. An example supporting 
the statement that especially the acute phase is of clinical relevance 
taBLe 8 | Outcomes of included studies investigating combined antithrombotic 
treatments use in patients with ischemic stroke who underwent acute 
mechanical thrombectomy.
Reference sicH, n/N (%) mortality, n/N (%) mRS (0–2), n/N (%)
Jeong et al. (26) T = 15/456 (3%)a T = 36/456 (8%) T = 256/456 (56%)
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, 
symptomatic intracranial hemorrhage; T, treated with antithrombotics.
aIntracranial hemorrhage resulting in NIHSS increase of ≥4.
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is the use of IV plasminogen activator in current practice. IV plas-
minogen activator seems safe when used within 4.5 h after stroke 
onset and improves functional outcome. However, extending this 
time window increases the risk of sICH significantly offsetting 
the beneficial effect (50). Possibly, as no clear distinction in time 
windows (i.e., acute or early) for antithrombotic treatment was 
made in most studies, the antithrombotic treatment effect may 
have been underestimated. Finally, sICH was defined according 
to various classifications, which makes it difficult to compare 
sICH risk among studies. Most studies elaborated on the exact 
sICH definition used (21–26, 28, 29, 31, 32, 34, 35, 38, 39). Most 
commonly, sICH was defined as neurologic deterioration with 
a 4 or more point increase in NIHSS score in combination with 
intracranial hemorrhage on imaging. Not all studies elaborated on 
the exact definition used. Therefore, heterogeneity among studies 
could have led to overestimation or underestimation of the actual 
risk. Due to the large variety in sample sizes and the heterogeneity 
between studies, a more in-depth exploration will not be helpful.
cONcLUSiON aND FUtURe DiRectiONS
Current evidence on periprocedural antiplatelet and heparin 
use in ischemic stroke patients undergoing acute MT relies 
on a limited number of post  hoc analyses and cohort studies. 
Methodological limitations of these studies warrant cautious 
interpretation of the results. RCTs investigating the effect of 
periprocedural antithrombotic treatment in MT are lacking. 
Some observational studies report a slight increase in sICH risk, 
which may be acceptable because they also suggest a beneficial 
effect on functional outcome. Well-conducted phase III RCTs 
focusing on the acute use of antithrombotic agents alone and in 
combinations during MT are therefore required. MR CLEAN-
MED (“Multicenter Randomized CLinical trial of Endovascular 
treatment for Acute ischemic stroke in the Netherlands; the effect 
of periprocedural MEDication: heparin, antiplatelet agents, both 
or neither”) is an ongoing phase III trial that investigates the effect 
of periprocedural intravenous use of aspirin and/or UFH on 
functional outcome of ischemic stroke patients undergoing MT 
(ISRCTN 76741621). We expect that this trial will provide better 
insights in the balance between potential risks and benefits of the 
use of these periprocedural antithrombotics for these patients.
aUtHOR cONtRiBUtiONS
RG, VC, and BR wrote the first draft of the manuscript and 
contributed to conception and design of the study; BR, DD, and 
AL supervised the study; all authors contributed to manuscript 
revision and read and approved the submitted version.
13
van de Graaf et al. Periprocedural Antithrombotics During MT
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 238
acKNOwLeDGmeNtS
We gratefully appreciate the support of our biomedical informa-
tion specialist, Gerdien B. de Jonge, Erasmus MC, who contrib-
uted to the literature search.
SUPPLemeNtaRy mateRiaL
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fneur.2018.00238/
full#supplementary-material.
ReFeReNceS
1. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, 
et  al. Endovascular thrombectomy after large-vessel ischaemic stroke: a 
meta-analysis of individual patient data from five randomised trials. Lancet 
(2016) 387(10029):1723–31. doi:10.1016/S0140-6736(16)00163-X 
2. Fransen PS, Berkhemer OA, Lingsma HF, Beumer D, van den Berg LA, Yoo AJ, 
et al. Time to reperfusion and treatment effect for acute ischemic stroke: a 
randomized clinical trial. JAMA Neurol (2016) 73(2):190–6. doi:10.1001/
jamaneurol.2015.3886 
3. Alexandrov AV, Hall CE, Labiche LA, Wojner AW, Grotta JC. Ischemic stun-
ning of the brain: early recanalization without immediate clinical improve-
ment in acute ischemic stroke. Stroke (2004) 35(2):449–52. doi:10.1161/01.
STR.0000113737.58014.B4 
4. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. 
Polymorphonuclear leukocytes occlude capillaries following middle cerebral 
artery occlusion and reperfusion in baboons. Stroke (1991) 22(10):1276–83. 
doi:10.1161/01.STR.22.10.1276 
5. Ember JA, del Zoppo GJ, Mori E, Thomas WS, Copeland BR, Hugli TE. 
Polymorphonuclear leukocyte behavior in a nonhuman primate focal isch-
emia model. J Cereb Blood Flow Metab (1994) 14(6):1046–54. doi:10.1038/
jcbfm.1994.137 
6. Mori E, del Zoppo GJ, Chambers JD, Copeland BR, Arfors KE. Inhibition 
of polymorphonuclear leukocyte adherence suppresses no-reflow after focal 
cerebral ischemia in baboons. Stroke (1992) 23(5):712–8. doi:10.1161/01.
STR.23.5.712 
7. Okada Y, Copeland BR, Fitridge R, Koziol JA, del Zoppo GJ. Fibrin contributes 
to microvascular obstructions and parenchymal changes during early focal 
cerebral ischemia and reperfusion. Stroke (1994) 25(9):1847–53; discussion 
53–4. doi:10.1161/01.STR.25.9.1847 
8. Dalkara T, Arsava EM. Can restoring incomplete microcirculatory reperfu-
sion improve stroke outcome after thrombolysis? J Cereb Blood Flow Metab 
(2012) 32(12):2091–9. doi:10.1038/jcbfm.2012.139 
9. Del Zoppo GJ, Copeland BR, Harker LA, Waltz TA, Zyroff J, Hanson SR, 
et  al. Experimental acute thrombotic stroke in baboons. Stroke (1986) 
17(6):1254–65. doi:10.1161/01.STR.17.6.1254 
10. Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES Jr, 
et  al. Reduced microvascular thrombosis and improved outcome in acute 
murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggrega-
tion. J Clin Invest (1998) 102(7):1301–10. doi:10.1172/JCI3338 
11. Bravo-Barrera J, Kourilovitch M, Galarza-Maldonado C. Neutrophil extra-
cellular traps, antiphospholipid antibodies and treatment. Antibodies (2017) 
6(1):1–12. doi:10.3390/antib6010004 
12. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, 
et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 
(2010) 107(36):15880–5. doi:10.1073/pnas.1005743107 
13. Laridan E, Denorme F, Desender L, Francois O, Andersson T, Deckmyn H, 
et al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 
(2017) 82(2):223–32. doi:10.1002/ana.24993 
14. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, 
case fatality, and functional outcome of intracerebral haemorrhage over time, 
according to age, sex, and ethnic origin: a systematic review and meta-analysis. 
Lancet Neurol (2010) 9(2):167–76. doi:10.1016/S1474-4422(09)70340-0 
15. Zinkstok SM, Roos YB; ARTIS Investigators. Early administration of aspirin 
in patients treated with alteplase for acute ischaemic stroke: a randomised 
controlled trial. Lancet (2012) 380(9843):731–7. doi:10.1016/S0140-6736(12) 
60949-0 
16. Sandercock P, Collins R, Counsell C, Farell B, Peto R, Slattery J, et  al. The 
International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous 
heparin, both, or neither among 19435 patients with acute ischaemic stroke. 
International Stroke Trial Collaborative Group. Lancet (1997) 349(9065):1569–81. 
17. Group CCaCR. Data Extraction Template for Cochrane Reviews: Cochrane 
Consumers and Communication Review Group. (2016). Available from: http://
cccrg.cochrane.org/author-resources (Accessed: December 8, 2017).
18. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et  al. 
Measurements of acute cerebral infarction: a clinical examination scale. Stroke 
(1989) 20(7):864–70. doi:10.1161/01.STR.20.7.864 
19. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver 
agreement for the assessment of handicap in stroke patients. Stroke (1988) 
19(5):604–7. doi:10.1161/01.STR.19.5.604 
20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. PLoS 
Med (2009) 6(7):e1000097. doi:10.1371/journal.pmed.1000097 
21. Behme D, Mpotsaris A, Zeyen P, Psychogios MN, Kowoll A, Maurer CJ, et al. 
Emergency stenting of the extracranial internal carotid artery in combination 
with anterior circulation thrombectomy in acute ischemic stroke: a retro-
spective multicenter study. AJNR Am J Neuroradiol (2015) 36(12):2340–5. 
doi:10.3174/ajnr.A4459 
22. Broeg-Morvay A, Mordasini P, Slezak A, Liesirova K, Meisterernst J, Schroth G, 
et al. Does antiplatelet therapy during bridging thrombolysis increase rates of 
intracerebral hemorrhage in stroke patients? PLoS One (2017) 12(1):e0170045. 
doi:10.1371/journal.pone.0170045 
23. Cohen JE, Gomori JM, Rajz G, Itshayek E, Eichel R, Leker RR. Extracranial 
carotid artery stenting followed by intracranial stent-based thrombectomy 
for acute tandem occlusive disease. J Neurointerv Surg (2015) 7(6):412–7. 
doi:10.1136/neurintsurg-2014-011175 
24. Ernst M, Butscheid F, Fiehler J, Wittkugel O, Alfke K, Jansen O, et  al. 
Glycoprotein IIb/IIIa inhibitor bridging and subsequent endovascular 
therapy in vertebrobasilar occlusion in 120 patients. Clin Neuroradiol (2016) 
26(2):169–75. doi:10.1007/s00062-014-0341-3 
25. Heck DV, Brown MD. Carotid stenting and intracranial thrombectomy for 
treatment of acute stroke due to tandem occlusions with aggressive antiplatelet 
therapy may be associated with a high incidence of intracranial hemorrhage. 
J Neurointerv Surg (2015) 7(3):170–5. doi:10.1136/neurintsurg-2014-011224 
26. Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ, Lee SH. Stroke outcomes 
with use of antithrombotics within 24 hours after recanalization treatment. 
Neurology (2016) 87(10):996–1002. doi:10.1212/WNL.0000000000003083 
27. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial 
of imaging selection and endovascular treatment for ischemic stroke. N Engl 
J Med (2013) 368(10):914–23. doi:10.1056/NEJMoa1212793 
28. Lockau H, Liebig T, Henning T, Neuschmelting V, Stetefeld H, Kabbasch C, 
et al. Mechanical thrombectomy in tandem occlusion: procedural consider-
ations and clinical results. Neuroradiology (2015) 57(6):589–98. doi:10.1007/
s00234-014-1465-5 
29. Marnat G, Mourand I, Eker O, Machi P, Arquizan C, Riquelme C, et  al. 
Endovascular management of tandem occlusion stroke related to internal 
carotid artery dissection using a distal to proximal approach: insight from 
the RECOST study. AJNR Am J Neuroradiol (2016) 37(7):1281–8. doi:10.3174/
ajnr.A4752 
30. Maurer CJ, Joachimski F, Berlis A. Two in one: endovascular treatment of 
acute tandem occlusions in the anterior circulation. Clin Neuroradiol (2015) 
25(4):397–402. doi:10.1007/s00062-014-0318-2 
31. Memon MZ, Natarajan SK, Sharma J, Mathews MS, Snyder KV, Siddiqui AH, 
et  al. Safety and feasibility of intraarterial eptifibatide as a revasculariza-
tion tool in acute ischemic stroke. J Neurosurg (2011) 114(4):1008–13. 
doi:10.3171/2010.8.JNS10318 
32. Mulder MJ, Berkhemer OA, Fransen PS, van den Berg LA, Lingsma HF, 
den Hertog HM, et al. Does prior antiplatelet treatment improve functional 
outcome after intra-arterial treatment for acute ischemic stroke? Int J Stroke 
(2017) 12(4):368–76. doi:10.1177/1747493016677842 
33. Nahab F, Walker GA, Dion JE, Smith WS. Safety of periprocedural 
heparin in acute ischemic stroke endovascular therapy: the multi 
14
van de Graaf et al. Periprocedural Antithrombotics During MT
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 238
MERCI trial. J Stroke Cerebrovasc Dis (2012) 21(8):790–3. doi:10.1016/j.
jstrokecerebrovasdis.2011.04.009 
34. Rangel-Castilla L, Rajah GB, Shakir HJ, Shallwani H, Gandhi S, Davies JM, 
et al. Management of acute ischemic stroke due to tandem occlusion: should 
endovascular recanalization of the extracranial or intracranial occlusive 
lesion be done first? Neurosurg Focus (2017) 42(4):E16. doi:10.3171/2017. 
1.FOCUS16500 
35. Stampfl S, Ringleb PA, Mohlenbruch M, Hametner C, Herweh C, Pham M, 
et al. Emergency cervical internal carotid artery stenting in combination with 
intracranial thrombectomy in acute stroke. AJNR Am J Neuroradiol (2014) 
35(4):741–6. doi:10.3174/ajnr.A3763 
36. Sugiura Y, Yamagami H, Sakai N, Yoshimura S; Committee of Recovery by 
Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Study Group. 
Predictors of symptomatic intracranial hemorrhage after endovascular ther-
apy in acute ischemic stroke with large vessel occlusion. J Stroke Cerebrovasc 
Dis (2017) 26(4):766–71. doi:10.1016/j.jstrokecerebrovasdis.2016.10.015 
37. Winningham MJ, Haussen DC, Nogueira RG, Liebeskind DS, Smith WS, 
Lutsep HL, et al. Periprocedural heparin use in acute ischemic stroke endovas-
cular therapy: the TREVO 2 trial. J Neurointerv Surg (2017):1–5. doi:10.1136/
neurintsurg-2017-013441 
38. Enomoto Y, Yoshimura S, Egashira Y, Yamagami H, Sakai N; Committee 
of Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Study 
Group. The risk of intracranial hemorrhage in Japanese patients with acute 
large vessel occlusion; subanalysis of the RESCUE-Japan registry. J Stroke 
Cerebrovasc Dis (2016) 25(5):1076–80. doi:10.1016/j.jstrokecerebrovasdis. 
2015.12.022 
39. Pandhi A, Tsivgoulis G, Krishnan R, Ishfaq MF, Singh S, Hoit D, et  al. 
Antiplatelet pretreatment and outcomes following mechanical thrombectomy 
for emergent large vessel occlusion strokes. J Neurointerv Surg (2017):1–6. 
doi:10.1136/neurintsurg-2017-013532 
40. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-
arterial prourokinase for acute ischemic stroke. The PROACT II study: a 
randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. 
JAMA (1999) 282(21):2003–11. doi:10.1001/jama.282.21.2003 
41. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et  al. 
Thrombolysis with alteplase for acute ischaemic stroke in the safe imple-
mentation of thrombolysis in stroke-monitoring study (SITS-MOST): 
an observational study. Lancet (2007) 369(9558):275–82. doi:10.1016/
S0140-6736(07)60149-4 
42. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et  al. 
Randomised double-blind placebo-controlled trial of thrombolytic therapy 
with intravenous alteplase in acute ischaemic stroke (ECASS II). Second 
European-Australasian Acute Stroke Study Investigators. Lancet (1998) 
352(9136):1245–51. doi:10.1016/S0140-6736(98)08020-9 
43. Chen ZM, Collins R, Liu LS, Pan HC, Peto R, Xie JX. CAST: randomised 
placebo-controlled trial of early aspirin use in 20,000 patients with acute 
ischaemic stroke. CAST (Chinese Acute Stroke Trial) Colla borative Group. 
Lancet (1997) 349(9066):1641–9. doi:10.1016/S0140-6736(97)04010-5 
44. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et  al. 
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl 
J Med (2008) 359(13):1317–29. doi:10.1056/NEJMoa0804656 
45. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study 
Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 
(1995) 333(24):1581–7. doi:10.1056/NEJM199512143332401 
46. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. 
PROACT: a phase II randomized trial of recombinant pro-urokinase by 
direct arterial delivery in acute middle cerebral artery stroke. PROACT 
Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke (1998) 
29(1):4–11. doi:10.1161/01.STR.29.1.4 
47. Nahab F, Kass-Hout T, Shaltoni HM. Periprocedural antithrombotic strat-
egies in acute ischemic stroke interventional therapy. Neurology (2012) 79 
(13 Suppl 1):S174–81. doi:10.1212/WNL.0b013e31826959af 
48. Widimsky P, Kocka V, Rohac F, Osmancik P. Periprocedural antithrombotic 
therapy during various types of percutaneous cardiovascular interventions. 
Eur Heart J Cardiovasc Pharmacother (2016) 2(2):131–40. doi:10.1093/ehjcvp/ 
pvv053 
49. Baird TA, Muir KW, Bone I. Basilar artery occlusion. Neurocrit Care (2004) 
1(3):319–29. doi:10.1385/NCC:1:3:319 
50. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, 
et  al. Association of outcome with early stroke treatment: pooled analysis 
of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 
363(9411):768–74. doi:10.1016/S0140-6736(04)15692-4 
Conflict of Interest Statement: RvdG has nothing to disclose. VC has nothing to 
disclose. GdZ has nothing to disclose. Erasmus MC received compensation from 
Stryker and Bracco Imaging Ltd for activities of DD and AL as a consultant. In 
addition, DD and AL are the recipients of unrestricted grants from Dutch Heart 
Foundation, Dutch Brain Foundation, Stryker and Penumbra for the conduct of 
trials on acute treatment for stroke. BR has nothing to disclose. RvdG, VC, DD, AL, 
and BR are investigators for the MR CLEAN-MED (ISRCTN 76741621).
Copyright © 2018 van de Graaf, Chalos, del Zoppo, van der Lugt, Dippel and 
Roozenbeek. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) and the copyright owner 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
